Artificial intelligence in bioinformatics focuses on merging computational technology with biological data to revolutionize drug discovery and development. Companies within this sector utilize high-throughput data analyses, machine learning algorithms, and innovative platforms to derive insights from complex genetic, genomic, and physiochemical information. This landscape sees firms ranging from established biotechs to rising startups, all targeting personalized medicine, predictive analytics, and treatment optimization. As the industry rapidly advances, expect a surge in AI capabilities, leading to more effective therapeutic options that cater to individual patient profiles, reducing clinical trial duration and cost.

This list covers 21 prominent AI bioinformatics companies exhibiting a spectrum of operational scales and specialties. With headquarters spread across North America, Europe, and Asia, these firms have been founded between 2000 and 2024, showcasing various focuses such as DNA data analysis, drug discovery, and genomic technologies. Sizes range from small teams to larger organizations, all driven by a shared goal of transforming healthcare through AI innovation. Each company is uniquely positioned to make significant strides in biological research, drug development, and data management, addressing critical challenges in the industry.

Read on to discover more about the top AI bioinformatics companies.

Top 21 AI Bioinformatics Companies

1. Deep Genomics

• Website: deepgenomics.com
• Ownership type: Venture Capital
• Headquarters: Toronto, Ontario, Canada
• Employee distribution: Canada 88%, United States (USA) 10%, Israel 2%
• Latest funding: Series C, $180.0M, July 2021
• Founded year: 2014
• Headcount: 51-200
• LinkedIn: deep-genomics

Deep Genomics is a biotechnology firm based in Toronto, Ontario, specializing in AI-driven drug development with a focus on RNA therapies. Founded in 2014, the company leverages its proprietary AI platform to navigate the complexities of RNA biology, aiming to identify novel therapeutic candidates for various genetic conditions. Their innovative approach not only accelerates drug discovery but also addresses the challenges posed by the vast and intricate data associated with RNA biology. Deep Genomics has made significant strides in the industry, including the release of their first Foundation Model for RNA Biology, BigRNA, in 2023, and they are currently developing BigRNA+ to expand their capabilities further. The company has attracted substantial investment, securing $180 million in a Series C funding round in July 2021, which underscores its potential and relevance in the biotechnology sector.

2. Insilico Medicine

• Website: insilico.com
• Ownership type: Private Equity
• Headquarters: Boston, Massachusetts, United States (USA)
• Employee distribution: China 43%, United Arab Emirates 20%, Hong Kong S.A.R 18%, Other 19%
• Latest funding: Series E-K, $110.0M, March 2025
• Founded year: 2014
• Headcount: 201-500
• LinkedIn: in-silico-medicine-inc

Insilico Medicine is a biotechnology firm based in Boston, Massachusetts, founded in 2014. The company is dedicated to transforming drug discovery and development through the application of artificial intelligence. Insilico offers a suite of AI-driven platforms, including PHARMA.AI, which facilitate various aspects of pharmaceutical research. Their technology aids in multi-omics target discovery, automated drug design, and predicting clinical trial outcomes. Insilico's clientele primarily consists of pharmaceutical companies and research institutions seeking to accelerate their drug development processes. The company has a global presence, with significant operations in China, the United Arab Emirates, and Hong Kong, in addition to its U.S. headquarters. Insilico has garnered substantial financial backing, with a recent funding round raising $110 million, reflecting strong investor interest in their innovative solutions and potential impact on the industry.

3. Ardigen

• Website: ardigen.com
• Ownership type: Private
• Headquarters: Kraków, Lesser Poland Voivodeship, Poland
• Employee distribution: Poland 91%, United States (USA) 5%, Other 4%
• Latest funding: $5.4M, September 2020
• Founded year: 2015
• Headcount: 51-200
• LinkedIn: ardigen-s-a-

Ardigen, founded in 2015 and based in Kraków, Poland, is a biotechnology firm that focuses on AI-driven solutions tailored for drug discovery and development. With a workforce of approximately 141 employees, Ardigen provides bioinformatics services and platforms, such as PhenAID, which help clients in the pharmaceutical and biotech sectors analyze complex biological data. The company emphasizes precision medicine, aiming to increase the probability of success in drug development. Ardigen has established partnerships with various industry leaders, showcasing their capability to deliver impactful solutions. They have also secured funding of $5.4 million as of September 2020, indicating investor confidence in their business model and growth potential.

4. BioSymetrics

• Website: biosymetrics.com
• Ownership type: Corporate
• Headquarters: Boston, Massachusetts, United States (USA)
• Employee distribution: Canada 61%, United States (USA) 39%
• Latest funding: February 2025
• Founded year: 2015
• Headcount: 11-50
• LinkedIn: biosymetrics

BioSymetrics is a biotechnology firm based in Boston, Massachusetts, founded in 2015. The company specializes in drug discovery and development, leveraging machine learning and phenomics to identify high-confidence targets for precision medicines. Their primary focus is on neurological, cardiometabolic, and rare diseases, with a notable emphasis on conditions such as epilepsy and familial dilated cardiomyopathy. BioSymetrics employs a platform called Elion, which connects vast datasets, including over 77 million patient records and 1 million genomic profiles, to enhance drug discovery processes. They collaborate with pharmaceutical companies and research organizations to improve clinical study designs and patient stratification. The company operates with a remote-first model, with team members distributed across the United States and Canada, and is committed to advancing the understanding of complex diseases through innovative data analysis.

5. Genoox

• Website: genoox.com
• Ownership type: Venture Capital
• Headquarters: Palo Alto, California, United States (USA)
• Employee distribution: Israel 90%, Spain 5%, Germany 5%
• Latest funding: Series B, $8.0M, February 2021
• Founded year: 2014
• Headcount: 11-50
• LinkedIn: genoox

Genoox, founded in 2014 and based in Palo Alto, California, is a healthcare technology company that specializes in genomic data analysis and solutions. The company offers a platform designed to provide insights for clinical genetics, biopharma, and healthcare systems, helping organizations optimize patient care and accelerate drug development. Genoox serves healthcare providers and research institutions globally, utilizing a community-driven approach to enhance genomic insights. Their technology is deployed in 44 countries and over 1,700 organizations, indicating a significant presence in the market. The company has received $8 million in Series B funding as of February 2021, which underscores its growth trajectory and the confidence investors have in its innovative solutions. Genoox aims to create the largest real-world evidence network of genomic and clinical data, making genomic data accessible and actionable at the point of care.

6. Gns

• Website: gnshealthcare.com
• Ownership type: Venture Capital
• Headquarters: Somerville, Massachusetts, United States (USA)
• Latest funding: $23.0M, July 2019
• Founded year: 2000
• Headcount: 51-200
• LinkedIn: gns-healthcare

Aitia, formerly known as Gns, is a biotechnology firm based in Somerville, Massachusetts, founded in 2000. The company specializes in AI-driven drug discovery and development, focusing on neurodegenerative diseases and oncology. Aitia employs causal AI and Gemini Digital Twins to analyze multi-omic patient data, aiming to reveal hidden biological mechanisms and accelerate the development of breakthrough therapeutics. Their innovative approach has attracted partnerships with various pharmaceutical companies and healthcare organizations, enhancing their position in the industry. Aitia has also secured significant funding, with a reported amount of $23 million in July 2019, which supports their ongoing research and development efforts.

7. Seven Bridges

• Website: sevenbridges.com
• Ownership type: Venture Capital
• Headquarters: Boston, Massachusetts, United States (USA)
• Latest funding: Series C, $15.0M, April 2021
• Founded year: 2009
• Headcount: 201-500
• LinkedIn: seven-bridges-inc

Seven Bridges, founded in 2009 and based in Boston, Massachusetts, is a biomedical data company that specializes in software and data analytics for healthcare research. The company provides bioinformatics solutions, particularly focusing on genomic data analysis, which is crucial for biopharma companies and research institutions. Their offerings include a range of products designed to streamline the path from raw experimental data to actionable insights, thereby facilitating the development of new treatments and diagnostics. Seven Bridges has also received significant funding, with a recent Series C round raising $15 million in April 2021, underscoring their relevance and potential in the bioinformatics field. Their platform supports collaborative research and development, enabling teams to connect and share data securely. With a commitment to enhancing the speed and efficiency of clinical trials and genomic research, Seven Bridges plays a vital role in advancing healthcare solutions.

8. Owkin

• Website: owkin.com
• Ownership type: Corporate
• Headquarters: New York, New York, United States (USA)
• Employee distribution: France 84%, United Kingdom (UK) 8%, United States (USA) 5%, Other 3%
• Latest funding: Series B, $50.0M, June 2022
• Founded year: 2016
• Headcount: 201-500
• LinkedIn: owkin

Owkin is a biotech company founded in 2016, headquartered in New York, with a significant presence in France and the UK. The company specializes in AI-driven drug discovery and diagnostics, utilizing advanced machine learning techniques to analyze complex biological data. Owkin collaborates with pharmaceutical companies and research institutions to optimize clinical trials and develop innovative diagnostic tools. Their approach integrates multimodal patient data, enabling a deeper understanding of disease mechanisms and improving patient outcomes. Notably, Owkin has developed AI diagnostics such as MSIntuit® for colorectal cancer and RlapsRisk® for breast cancer, which assist healthcare providers in making informed treatment decisions. The company has raised $50 million in its latest funding round, reflecting strong investor interest in its mission to transform drug discovery and development through AI.

9. BenchSci

• Website: benchsci.com
• Ownership type: Venture Capital
• Headquarters: Toronto, Ontario, Canada
• Employee distribution: Canada 94%, United Kingdom (UK) 5%, Other 1%
• Latest funding: Series D, $69.6M, May 2023
• Founded year: 2015
• Headcount: 201-500
• LinkedIn: benchsci

BenchSci, founded in 2015 and based in Toronto, Ontario, is a biotechnology company that specializes in AI-driven solutions aimed at improving drug discovery and research and development processes. The company has developed the ASCEND platform, which serves as a science-first generative AI assistant designed to enhance the workflows of pharmaceutical companies and academic institutions. By leveraging a comprehensive biomedical dataset, including closed access papers and patents, BenchSci aims to provide researchers with the tools necessary to make informed experimental decisions. The company has gained traction in the industry, with over 4,300 academic institutions and 16 of the top 20 pharmaceutical companies utilizing its AI solutions. Recently, BenchSci raised $95 million in Series D funding, which will enable further enhancements to its platform and support its mission to accelerate drug discovery and improve patient outcomes.

10. Biorelate

• Website: biorelate.com
• Ownership type: Private Equity
• Headquarters: Manchester, England, United Kingdom (UK)
• Employee distribution: United Kingdom (UK) 90%, Germany 10%
• Latest funding: Series A, $7.8M, November 2022
• Founded year: 2014
• Headcount: 11-50
• LinkedIn: biorelate-limited

Biorelate, founded in 2014 and based in Manchester, UK, is a biotechnology company that specializes in advanced data curation and bioinformatics solutions. The company has developed the Galactic AI™ platform, which enables biopharmaceutical companies and researchers to uncover critical insights from vast amounts of biomedical literature, thereby supporting drug discovery efforts. Biorelate's technology focuses on identifying cause-and-effect relationships among drugs, genes, and diseases, which is essential for understanding complex biological processes. The company has established a strong presence in the industry, serving major pharmaceutical firms and innovative biotech companies. With a workforce of around 40 employees, Biorelate has demonstrated its commitment to enhancing research capabilities through data analysis. The company successfully raised over 7.7 million in Series A funding in late 2022, reflecting its growth potential and the increasing demand for its services in the biopharma sector.

11. Deargen

• Website: deargen.me
• Ownership type: Venture Capital
• Headquarters: Daejeon, Daejeon, South Korea
• Employee distribution: South Korea 100%
• Latest funding: Series B, $16.6M, February 2022
• Founded year: 2016
• Headcount: 51-200
• LinkedIn: deargen

Deargen Inc. is a biotechnology company based in Daejeon, South Korea, founded in 2016. The firm specializes in AI-driven drug discovery and development, offering a range of services that include genome data analysis, biomarker prediction, and lead optimization. By utilizing advanced AI technologies, Deargen aims to transform the treatment of diseases that are often considered difficult to address. The company has established partnerships with various pharmaceutical firms and research institutions, enhancing its role in the industry. In February 2022, Deargen secured approximately $16.6 million in Series B funding, which underscores its growth potential and commitment to innovation in drug development.

12. Strand Life Sciences

• Website: strandls.com
• Ownership type: Corporate
• Headquarters: Bengaluru, Karnataka, India
• Employee distribution: India 99%, Other 1%
• Latest funding: $53.8M, September 2021
• Founded year: 2000
• Headcount: 201-500
• LinkedIn: strand-life-sciences

Strand Life Sciences, founded in 2000 and based in Bengaluru, Karnataka, India, is a genomics company that specializes in bioinformatics and software development for life sciences research. With a workforce of over 600 employees, the company has built a reputation for providing advanced solutions in next-generation sequencing (NGS) and polymerase chain reaction (PCR) diagnostics. Their services extend to pharmaceutical and biomarker discovery, as well as custom software development tailored to the needs of their clients, which include prominent pharmaceutical companies and diagnostic laboratories. Strand Life Sciences has successfully completed over 500 projects in genomics, showcasing their extensive experience in the field. They have developed platforms such as StrandNGS for secondary analysis and StrandOmics for variant classification, which are integral to their operations. The company has also secured significant funding, with the last reported amount being over $53 million in September 2021, indicating ongoing investor confidence in their capabilities and future prospects.

13. CytoReason

• Website: cytoreason.com
• Ownership type: Venture Capital
• Headquarters: Tel Aviv-Yafo, Tel Aviv, Israel
• Employee distribution: Israel 97%, United States (USA) 3%
• Latest funding: Series B, $80.0M, July 2024
• Founded year: 2016
• Headcount: 51-200
• LinkedIn: cytoreason

CytoReason, founded in 2016 and based in Tel Aviv-Yafo, Israel, is a biotechnology company that leverages artificial intelligence to create disease models for drug discovery and development. The company focuses on transforming complex molecular data into actionable insights for pharmaceutical companies and research institutions. Their solutions include drug portfolio management, patient stratification, and indication assignment, all aimed at improving the success rates of clinical trials. CytoReason has established partnerships with major pharmaceutical firms, including a recent collaboration with Sanofi to license their inflammatory bowel disease model. The company has also secured significant funding, with an $80 million Series B round in July 2024, backed by investors such as OurCrowd, NVIDIA, and Thermo Fisher Scientific. This funding will help CytoReason expand its AI disease models and establish a presence in the United States.

14. Abzu

• Website: abzu.ai
• Ownership type: Venture Capital
• Headquarters: Copenhagen, Denmark
• Employee distribution: Spain 50%, Denmark 50%
• Latest funding: Other (Grant), $2.4M, October 2022
• Founded year: 2018
• Headcount: 11-50
• LinkedIn: abzu

Abzu, founded in 2018 and based in Copenhagen, Denmark, is an AI research company that specializes in providing innovative solutions for the pharmaceutical and biotechnology industries. With a team of around 25 employees, Abzu focuses on advanced AI-driven services, particularly in biomarker identification and RNA therapeutics design. Their proprietary technology, QLattice, is designed to improve drug discovery by offering insights that are not only accurate but also explainable, addressing a critical need in the industry for transparency in AI applications. Abzu has engaged in significant projects, including collaborations with NASA GeneLab to study dermatological changes in spaceflight and partnerships aimed at designing safe and effective RNA therapeutics. The company has also secured funding, including a grant of approximately 2.4 million euros in 2022, which supports its ongoing research and development efforts.

15. Causaly

• Website: causaly.com
• Ownership type: Venture Capital
• Headquarters: London, England, United Kingdom (UK)
• Employee distribution: United Kingdom (UK) 62%, Greece 21%, United States (USA) 12%, Other 5%
• Latest funding: Series B, $60.0M, July 2023
• Founded year: 2018
• Headcount: 51-200
• LinkedIn: causaly

Causaly is a technology company based in London, England, founded in 2018. It focuses on providing AI solutions specifically for the life sciences sector. The company has developed a generative AI platform that enhances research productivity and automates knowledge processes for pharmaceutical and biotechnology companies. Causaly's tools facilitate target identification, biomarker discovery, and disease biology analysis, which are critical components in the drug discovery process. The platform has been adopted by 12 of the top 20 pharmaceutical companies, showcasing its relevance and utility in the industry. In July 2023, Causaly secured $60 million in Series B funding, reflecting strong investor interest and confidence in its innovative approach to bioinformatics and research efficiency.

16. PathAI

• Website: pathai.com
• Ownership type: Corporate
• Headquarters: Boston, Massachusetts, United States (USA)
• Employee distribution: United States (USA) 99%, Other 1%
• Latest funding: May 2024
• Founded year: 2016
• Headcount: 501-1000
• LinkedIn: pathai

PathAI, founded in 2016 and based in Boston, Massachusetts, is a healthcare technology company that specializes in AI-powered pathology solutions. The company develops advanced AI models designed to enhance the analysis of patient tissue samples. This technology supports biopharmaceutical companies and pathology laboratories in improving diagnostic accuracy and accelerating drug development processes. PathAI's offerings include the AI Sight digital pathology platform and various lab services. They have built a proprietary network of over 450 pathologists, contributing more than 15 million annotations to train and validate their AI models. This extensive data collection allows PathAI to deliver transformative tools that help pathologists make more accurate diagnoses and expedite the approval of life-saving therapies. In 2021, PathAI secured $165 million in Series C funding, which has bolstered their research and development capabilities. The company has also expanded into clinical diagnostics and built an in-house CAP/CLIA-certified histopathology lab to support clinical trials for their biopharma partners. Their recent strategic partnership with Quest Diagnostics further solidifies their position in the market.

17. 3bigs CO., LTD.

• Website: 3bigs.com
• Ownership type: Private
• Headquarters: Hwaseong-Si, Gyeonggi-Do, South Korea
• Employee distribution: India 58%, South Korea 42%
• Latest funding: $2.0M, October 2024
• Founded year: 2018
• Headcount: 11-50
• LinkedIn: 3bigs-co-limited

3bigs CO., LTD., founded in 2018 and based in Hwaseong-Si, Gyeonggi-Do, South Korea, is a private bioinformatics firm with a workforce of approximately 26 employees. The company specializes in advanced data analysis and drug discovery solutions, providing services that include next-generation sequencing (NGS) data analysis, cheminformatics, and AI/ML integrated solutions. Their offerings are tailored to meet the needs of businesses and organizations in the healthcare and pharmaceutical sectors, aiming to enhance research and development efficiency. 3bigs has a significant presence in India, accounting for 58% of its employee distribution, which reflects its strategic approach to tapping into global talent. The company has also secured funding of approximately $1.97 million in October 2024, underscoring its active engagement in the industry and potential for future growth.

18. InveniAI

• Website: inveniai.com
• Ownership type: Private
• Headquarters: Guilford, Connecticut, United States (USA)
• Latest funding: $3.1M, June 2024
• Founded year: 2017
• Headcount: 11-50
• LinkedIn: inveniai

InveniAI, founded in 2017 and based in Guilford, Connecticut, is a technology company that specializes in the application of artificial intelligence (AI) and machine learning (ML) to accelerate drug discovery and development. The company aims to transform the identification and development of therapies for diseases with unmet medical needs. Their primary offering, the AlphaMeld® platform, integrates complex scientific, medical, chemical, and biological data to facilitate rapid decision-making for drug developers. InveniAI has formed over 150 collaborations with various stakeholders in the biopharmaceutical sector, demonstrating its commitment to addressing critical challenges in drug development. The company has also received $3.1 million in funding as of June 2024, which supports its ongoing efforts to innovate and expand its technology. InveniAI's work is particularly focused on enhancing the efficiency of drug discovery processes, making it a significant player in the life sciences industry.

19. Omic

• Website: omic.ai
• Ownership type: Private
• Headquarters: Seattle, Washington, United States (USA)
• Employee distribution: United States (USA) 74%, Vietnam 26%
• Founded year: 2017
• Headcount: 11-50
• LinkedIn: omicmd

Omic is a private biomedical research company based in Seattle, Washington, founded in 2017. With a team of approximately 27 employees, Omic specializes in creating an AI platform designed for multi-omic discoveries. The company aims to revolutionize therapy design and drug testing by providing solutions tailored for researchers and pharmaceutical companies. Their platform utilizes advanced machine learning techniques and a vast biomedical knowledge graph to optimize treatment strategies. Notably, Omic has pioneered the development of CAR therapies through deep learning and has created digital patient cohorts for testing drugs, which enhances the drug discovery process. Their innovative approach positions them as a significant player in the bioinformatics industry, focusing on generating novel therapies and improving drug development efficiency.

20. BioMap

• Website: biomap.com
• Ownership type: Venture Capital
• Headquarters: Palo Alto, California, United States (USA)
• Employee distribution: China 79%, United States (USA) 19%, United Arab Emirates 2%
• Latest funding: June 2024
• Founded year: 2020
• Headcount: 201-500
• LinkedIn: biomap2020

BioMap, founded in 2020 and based in Palo Alto, California, is a biotechnology firm that specializes in AI-driven solutions for the life sciences. The company has developed advanced AI Foundation Models aimed at facilitating drug discovery and protein design, catering to the needs of pharmaceutical and biotech firms. Their flagship model, xTrimo, is notable for its ability to generate rapid and accurate predictions regarding protein behavior, addressing critical challenges in the industry. BioMap's innovative approach includes the use of extensive proprietary datasets, which comprise over 6 billion proteins and 100 billion protein-protein interactions. The company has also established a high-throughput wet lab and a super-computing center to support its research initiatives. BioMap has gained significant attention in the industry, evidenced by its strategic collaborations with major players like Sanofi and GeneQuantum, aimed at accelerating drug discovery and developing next-generation therapeutics. Additionally, the company successfully raised $100 million in Series A funding, which underscores investor confidence in its potential to drive advancements in life sciences through AI.

21. DNAnexus

• Website: dnanexus.com
• Ownership type: Private Equity
• Headquarters: Mountain View, California, United States (USA)
• Employee distribution: Czech Republic 49%, United States (USA) 42%, Vietnam 5%, Other 4%
• Latest funding: Series E-K, $200.0M, March 2022
• Founded year: 2009
• Headcount: 201-500
• LinkedIn: dnanexus

DNAnexus is a private equity-backed company based in Mountain View, California, founded in 2009. It operates a cloud-based platform designed for the management and analysis of DNA sequence data. The company serves a wide array of biomedical organizations, including pharmaceutical companies, academic medical centers, and clinical diagnostics firms. DNAnexus provides a comprehensive suite of bioinformatics tools that facilitate data analysis, collaboration, and compliance with industry regulations. Their platform supports next-generation sequencing (NGS) data analysis, translational informatics, and population genomics, among other applications. With over 105 petabytes of precision health data on their platform and a user base exceeding 45,000, DNAnexus is positioned as a significant player in the bioinformatics field. The company secured $200 million in Series E funding in March 2022, which underscores its ongoing relevance and potential for growth in the industry.

AI Bioinformatics Insights: Key Companies

Company	Headquarter	Size	Founded	Ownership
Deep Genomics	Toronto, Ontario, Canada	51-200	2014	Venture Capital
Insilico Medicine	Boston, Massachusetts, United States (USA)	201-500	2014	Private Equity
Ardigen	Kraków, Lesser Poland Voivodeship, Poland	51-200	2015	Private
BioSymetrics	Boston, Massachusetts, United States (USA)	11-50	2015	Corporate
Genoox	Palo Alto, California, United States (USA)	11-50	2014	Venture Capital
Gns	Somerville, Massachusetts, United States (USA)	51-200	2000	Venture Capital
Seven Bridges	Boston, Massachusetts, United States (USA)	201-500	2009	Venture Capital
Owkin	New York, New York, United States (USA)	201-500	2016	Corporate
BenchSci	Toronto, Ontario, Canada	201-500	2015	Venture Capital
Biorelate	Manchester, England, United Kingdom (UK)	11-50	2014	Private Equity
Deargen	Daejeon, Daejeon, South Korea	51-200	2016	Venture Capital
Strand Life Sciences	Bengaluru, Karnataka, India	201-500	2000	Corporate
CytoReason	Tel Aviv-Yafo, Tel Aviv, Israel	51-200	2016	Venture Capital
Abzu	Copenhagen, Denmark	11-50	2018	Venture Capital
Causaly	London, England, United Kingdom (UK)	51-200	2018	Venture Capital
PathAI	Boston, Massachusetts, United States (USA)	501-1000	2016	Corporate
3bigs CO., LTD.	Hwaseong-Si, Gyeonggi-Do, South Korea	11-50	2018	Private
InveniAI	Guilford, Connecticut, United States (USA)	11-50	2017	Private
Omic	Seattle, Washington, United States (USA)	11-50	2017	Private
BioMap	Palo Alto, California, United States (USA)	201-500	2020	Venture Capital
DNAnexus	Mountain View, California, United States (USA)	201-500	2009	Private Equity

Want to Find More AI Bioinformatics Companies?

If you want to find more companies that offer AI-driven solutions for drug discovery and genomic analysis you can do so with Inven. This list was built with Inven and there are hundreds of companies like these globally.

With Inven you'll also get to know the company's:

• Detailed Ownership: Who owns the company? Is it a public or private company? What is the ownership structure?
• Contact data: Who are the founders and CEO's? What are their emails and phone numbers?
• Financials: How do these companies perform financially? What are their revenues and profit margins?

...and a lot more!